What happened with VTGN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Vistagen Therapeutics is a clinical-stage drug developer focused on fasedienol, a nasal-spray candidate for social anxiety disorder in U.S. Phase 3 trials. Its other nasal-spray candidates target conditions including depression and menopausal hot flashes. None of its candidates is approved for sale, and it has never generated product-sales revenue.
AffaMed paid Vistagen upfront for exclusive rights to develop, manufacture and commercialize fasedienol in Greater China, South Korea and specified Southeast Asian countries. AffaMed covers development and commercialization costs there; Vistagen retains rights elsewhere. The agreement could bring further payments as development, approval and sales milestones are met, plus royalties on sales after approval, but these payments are not assured. Vistagen also has a negotiation agreement with Fuji Pharma that contributes to its agreement-based revenue.
The business depends chiefly on advancing fasedienol through trials and securing regulatory approval. The FDA has requested additional studies or data to support approval for acute treatment of social anxiety disorder. Vistagen outsources manufacturing and has funded operations mainly by selling equity. It needs additional capital and currently lacks the resources to continue developing its other candidates or commercialize any candidate.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Vistagen’s prospects depend chiefly on fasedienol’s Phase 3 results and financing, while AffaMed holds its development and commercialization rights in Greater China, South Korea and specified Southeast Asian countries.
Vanda Pharmaceuticals Inc. is a potential rival to Vistagen’s lead drug fasedienol: Vistagen lists it among companies developing or potentially developing treatments for acute social anxiety. Vanda already sells medicines for conditions including schizophrenia and bipolar I disorder, but its acute social anxiety development—not those existing sales—is the news to watch for fasedienol.
Tonix Pharmaceuticals Holding Corp. could compete with Vistagen’s fasedienol through treatments it is developing or may develop for acute social anxiety. Tonix already sells TONMYA for adult fibromyalgia and medicines for acute migraine; progress in acute social anxiety would be the more direct signal for Vistagen.
Definium Therapeutics, Inc.’s DT120 ODT targets the same major depressive disorder patients as Vistagen’s itruvone, making its Phase 3 depression results worth watching for competition. DT120 is still investigational, and its lysergide ingredient would need a change in U.S. controlled-substance classification after FDA approval before it could be prescribed.
Axsome Therapeutics, Inc already sells AUVELITY to treat major depressive disorder, so Vistagen’s itruvone would enter a patient market with an established rival. AUVELITY sales are the relevant line to watch, rather than Axsome’s combined revenue from depression, daytime sleepiness and migraine medicines.
Neumora Therapeutics, Inc. is developing depression medicines that could compete for the patients Vistagen targets with itruvone. Through December 31, 2025, Neumora had no approved or commercialized products and no product-sales revenue, so clinical development and approval news—not medicine sales—are the signals to watch.
Xenon Pharmaceuticals Inc’s azetukalner is in Phase 3 trials for major depressive disorder, putting it in competition with Vistagen’s itruvone program. Watch the depression trial results specifically: azetukalner is also being tested for epilepsy and bipolar depression, and remains an investigational drug rather than a product being sold.
GH Research PLC develops depression treatments that Vistagen identifies as potential competitors to itruvone. If GH001 or GH002 is approved, GH Research plans to reach healthcare providers, clinic networks and third-party payors in the United States and major European markets, making approval and commercial launch plans relevant to the competition itruvone could face.
COMPASS Pathways Plc’s COMP360 targets treatment-resistant depression, overlapping with the broader depression market Vistagen’s itruvone aims to serve rather than the same exact patient group. If approved, COMPASS plans to market its psilocybin treatment to U.S. healthcare providers and clinic networks; its progress toward that market is the competitive development to watch.
Axsome Therapeutics, Inc earningsAXSM
Axsome Therapeutics’ report will show AUVELITY sales, revealing the commercial traction of an established treatment in the depression market Vistagen’s itruvone aims to enter.
Focus on AUVELITY sales, not Axsome’s combined revenue, which also includes medicines for daytime sleepiness and migraine. Stronger AUVELITY sales would show an established treatment gaining commercial traction in the depression market, giving any future itruvone launch a rival with a sales base to contend with. Weaker sales would show less traction for this treatment, but would not establish itruvone’s efficacy or demand.
Vanda Pharmaceuticals Inc. earningsVNDA
If Vanda Pharmaceuticals’ report gives an update on its acute social anxiety program, it will show how a potential rival to Vistagen’s lead candidate, fasedienol, is progressing.
Look for clinical or regulatory progress on Vanda’s acute social anxiety program; sales of its marketed schizophrenia and bipolar I medicines are not the relevant signal here. A concrete advance would show another candidate moving toward the same patient need and could mean more direct future competition for fasedienol. If no progress is reported, this report offers no evidence that this potential rival has moved forward.
Vistagen Therapeutics, Inc. earningsThis company
Vistagen Therapeutics has no approved-product sales, so its report will show whether cash and development spending can still support its drug candidates.
Read research and development and administrative costs alongside operating cash use and the ending cash balance. Controlled costs and slower cash use would leave more resources to support clinical development; rising costs and continued rapid cash depletion would increase pressure to raise funds or scale back programs. Licensing revenue can depend on milestones and the timing of revenue recognition, so a quarterly revenue change is not a change in product demand. The conclusion is whether available cash can support development plans.
